High Flow Nasal Cannula Therapy (HFNC) Versus Nasal Positive Airway Pressure and or Nasal Positive Pressure Ventilation (NCPAP/ NPPV) in Infants With Severe Bronchiolitis
Bronchiolitis
About this trial
This is an interventional supportive care trial for Bronchiolitis
Eligibility Criteria
Inclusion Criteria:
- Clinical diagnosis of bronchiolitis defined as the first viral episode of respiratory distress before 2 years of aging, presenting with rhinitis, tachypnea, cough, wheezing, prolonged expiratory time, crackles and use of accessory muscles, with or without fever, with or without infiltrate on the chest X ray
- bronchiolitis severity Wang modified score ≥ 10
Exclusion Criteria:
- recurrent wheezing
- heart disease
- chronic lung disease
- neuromuscular disease
- primary diagnosis was not bronchiolitis (pneumonia, pertussis)
- critically ill infants who had an immediate need of intubation
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
high flow nasal cannula (HFNC)
nasal continuous positive airway pressure / nasal positive pressure ventilation (NCPAP/NPPV)
Participants in the HFNC group received heated and humidified gas flow with the Fisher & Paykel Healthcare HFNC system. The flow rate was usually started at the maximum flow rate for the size of cannula and a constant flow temperature of 37 °C.The flow rate will be progressively decreased when inspired fraction of oxygen (FiO2) was inferior to 30 percent (%).
Participants in the CPAP/NPPV group received for first CPAP using a neonatal ventilator. The recommended starting pressure for CPAP was +6 centimeter of water (cmH2O). Positive continuous pressure could be increased to a maximum of +8 cmH2O. Optimal positive end expiratory pressure (PEEP) was what could maintain SpO2 at 94 per cent using the lowest fraction of inspired oxygen. PEEP will be decreased progressively of 1cmH2O every 6 hours from the optimal PEEP when FiO2 was inferior to 30% and there is no increase of work of breath.